Myeloproliferative disease
|
0.200 |
GeneticVariation
|
group |
BEFREE |
A 2.5-year-old boy was diagnosed with myeloproliferative disorder and eosinophilia associated with lymphoblastic lymphoma both bearing the CCDC88C-PDGFRB fusion.
|
30726835 |
2019 |
Myeloproliferative disease
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Although patients with PDGFRB rearrangement mostly present with myeloproliferative neoplasm and eosinophilia, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) have also been reported in this population.
|
28000100 |
2017 |
Myeloproliferative disease
|
0.200 |
Biomarker
|
group |
BEFREE |
We report a NUMA1-PDGFRB fusion in a myeloproliferative neoplasm with eosinophilia in a 61-year old man, with response to imatinib mesylate therapy.
|
28449810 |
2017 |
Myeloproliferative disease
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Myeloid neoplasms and eosinophilia with rearrangements of PDGFRB are uncommon Philadelphia-negative myeloproliferative neoplasms.
|
24687085 |
2014 |
Myeloproliferative disease
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Myeloproliferative neoplasms associated with FIP1L1-PDGFR rearrangements represent a rare subset of myeloid and lymphoid malignancies, characterised by the presence of eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1 genes.
|
24460680 |
2014 |
Myeloproliferative disease
|
0.200 |
Biomarker
|
group |
BEFREE |
Here, we developed version 2.0 of a genomically based systematic kinase fusion screen and used it to detect a novel imatinib-sensitive C6orf204-PDGFRB fusion in a patient with precursor T lymphoblastic lymphoma (T-ALL) and an associated myeloproliferative neoplasm with eosinophilia.
|
21938754 |
2012 |
Myeloproliferative disease
|
0.200 |
GeneticVariation
|
group |
BEFREE |
The incidence of myeloproliferative neoplasms (MPN) with PDGFRB rearrangement was low (10 cases, 1.8% of all MPN).
|
22587685 |
2012 |
Myeloproliferative disease
|
0.200 |
Biomarker
|
group |
BEFREE |
The introduction of JAK2 mutation testing has changed dramatically the diagnostic algorithms for myeloproliferative neoplasms (MPNs) but there is still a place for conventional cytogenetic analysis in the initial work-up of MPN cases, particularly as this group of myeloid disorders has been expanded to include chronic eosinophilic leukaemia and myeloid neoplasms with abnormalities of the PDGFRA, PDGFRB, and FGFR1 genes.
|
21431636 |
2011 |
Myeloproliferative disease
|
0.200 |
Biomarker
|
group |
BEFREE |
Important changes include (1) the change of nomenclature of myeloproliferative disorder to myeloproliferative neoplasm emphasizing the clonal nature of these disorders; (2) the classification of mast cell disease as an MPN; (3) the reorganization of the eosinophilic disorders into a molecularly defined category of PDGFRA, PDGFRB and FGFR1-associated myeloid and lymphoid neoplasms with eosinophilia and chronic eosinophilic leukemia, not otherwise specified; and (4) refinement of the diagnostic criteria for PV, ET and PMF incorporating recently described molecular markers, JAK2V617F, JAK2 exon 12 mutations and MPL mutations.
|
20191332 |
2010 |
Myeloproliferative disease
|
0.200 |
GeneticVariation
|
group |
BEFREE |
This review highlights the important diagnostic tools in classical and atypical myeloproliferative neoplasms mainly the JAK2V617F mutation, the Mpl receptor, Polycythemia rubra vera 1 (PRV1), platelet-derived growth-factor receptor alpha (PDGFRA), platelet-derived growth-factor receptor beta (PDGFRB), fibroblast growth-factor receptor 1 (FGFR1) and c-kit tyrosine kinase.
|
20126996 |
2010 |
Myeloproliferative disease
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Quantitative reverse transcriptase polymerase chain reaction analysis is a simple and useful adjunct to standard diagnostic assays to detect clinically significant overexpression of PDGFRA and PDGFRB in eosinophilia-associated myeloproliferative neoplasms or related disorders.
|
20107158 |
2010 |
Myeloproliferative disease
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Identification of a MYO18A-PDGFRB fusion gene in an eosinophilia-associated atypical myeloproliferative neoplasm with a t(5;17)(q33-34;q11.2).
|
19006078 |
2009 |
Myeloproliferative disease
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Tel/PDGFRbeta results in constitutive activation of several signaling pathways and induces a myeloproliferative disease in mice, with signals via tyrosines 579/581 identified as being important for this phenotype.
|
19100521 |
2009 |
Myeloproliferative disease
|
0.200 |
Biomarker
|
group |
BEFREE |
Therapeutically validated oncoproteins in myeloproliferative neoplasms (MPN) include BCR-ABL1 and rearranged PDGFR proteins.The latter are products of intra- (e.g.
|
19175693 |
2009 |
Myeloproliferative disease
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Imatinib is usually a highly effective treatment for myeloproliferative neoplasms (MPNs) associated with ABL, PDGFRA or PDGFRB gene fusions; however, occasional imatinib-responsive patients have been reported without abnormalities of these genes.
|
18971950 |
2009 |
Myeloproliferative disease
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Myeloid neoplasms are now classified into five categories: acute myeloid leukemia, myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), MDS/MPN, and myeloid and/or lymphoid malignancies associated with eosinophilia and PDGFR or FGFR1 rearrangements.
|
19806146 |
2009 |
Myeloproliferative disease
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Therapeutically validated oncoproteins in myeloproliferative neoplasms (MPNs) include BCR-ABL in chronic myelogenous leukemia (CML) and a spectrum of PDGFRA/B mutant proteins that are products of intra- (eg, FIP1L1-PDGFRA) or interchromosomal (eg, ETV6-PDGFRB) gene fusions.
|
19147089 |
2009 |
Myeloproliferative disease
|
0.200 |
AlteredExpression
|
group |
LHGDN |
Platelet-derived growth factor may be associated with fibrosis in a Down syndrome patient with transient myeloproliferative disorder.
|
18331602 |
2008 |
Myeloproliferative disease
|
0.200 |
Biomarker
|
group |
LHGDN |
Fusion of PRKG2 and SPTBN1 to the platelet-derived growth factor receptor beta gene (PDGFRB) in imatinib-responsive atypical myeloproliferative disorders.
|
18262053 |
2008 |
Myeloproliferative disease
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Fusion of PRKG2 and SPTBN1 to the platelet-derived growth factor receptor beta gene (PDGFRB) in imatinib-responsive atypical myeloproliferative disorders.
|
18262053 |
2008 |
Myeloproliferative disease
|
0.200 |
AlteredExpression
|
group |
LHGDN |
Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene.
|
17296564 |
2007 |
Myeloproliferative disease
|
0.200 |
GeneticVariation
|
group |
BEFREE |
KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32).
|
15496975 |
2005 |
Myeloproliferative disease
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Lack of response to imatinib mesylate in a patient with accelerated phase myeloproliferative disorder with rearrangement of the platelet-derived growth factor receptor beta-gene.
|
15477214 |
2004 |
Myeloproliferative disease
|
0.200 |
GeneticVariation
|
group |
BEFREE |
NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorder.
|
15087377 |
2004 |
Myeloproliferative disease
|
0.200 |
GeneticVariation
|
group |
BEFREE |
p53-Binding protein 1 is fused to the platelet-derived growth factor receptor beta in a patient with a t(5;15)(q33;q22) and an imatinib-responsive eosinophilic myeloproliferative disorder.
|
15492236 |
2004 |